Is the 'Death Sentence' Officially Over? For decades, pancreatic cancer was medicine’s ultimate "greased ball"—slippery, untouchable, and notoriously lethal. But in 2026, the medical world just entered 'God Mode.' 🚀 In this episode, we’re dismantling the "undruggable" defenses of the most feared cancer diagnosis. We dive into the ASCO 2026 standing ovation for Daraxonrasib, the drug that finally bound to the KRAS G12D mutation, and how NALIRIFOX is literally smashing through the tumor's fibrous shield. Why you need to listen: - The RAS Revolution: We break down why survival rates just doubled in the RASolute 302 trial. - Immune Reprogramming: Discover how mRNA vaccines like Autogene Cevumeran are training your body to hunt cancer cells before they return. - The $100k Barrier: Can we actually afford the cure, or will access remain a luxury? This isn't just medical news; it's a front-row seat to the end of an era of despair. Whether you're a patient, a researcher, or just someone who loves high-stakes innovation, this story of precision oncology is the hope we've been waiting for. ✨ Subscribe now to stay at the cutting edge of human survival. Let's change the narrative together!  

New clinical trial data show KRAS-blocking drugs may significantly improve survival for the disease. “I think this is truly an earth-shattering moment in pancreatic cancer.”

An early report of a new type of CAR T cell therapy, called KIR-CAR, was shared in a Clinical Trial Plenary session at the AACR Annual Meeting 2026.

Breast cancer is the most common cancer in females worldwide, and the incidence rate in China has been increasing in recent decades. The treatment of breast cancer with cyclophosphamide (CTX) is one ...

Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma who received immunotherapy beyond the standard 2 years.

Learn how new research of the traces life-saving pediatric cancer treatments leave in DNA could help improve the detection and prevention of second neoplasms.

SAN DIEGO – Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug c...

Nobody expects to get cancer in their 20s, but I was 28 when I was diagnosed with Hodgkin lymphoma.

The research on bone-marrow transplantation mirrors the arc of many medical advancements. I was one of the early beneficiaries.

Long-term adverse events were rare and manageable among patients with alveolar soft part sarcoma who received immunotherapy beyond the standard 2 years.

Learn how new research of the traces life-saving pediatric cancer treatments leave in DNA could help improve the detection and prevention of second neoplasms.

SAN DIEGO – Patients with advanced platinum-resistant ovarian cancer whose disease had progressed on standard therapy experienced clinical benefit when treated with the investigational antibody-drug c...

We previously reported initial results of the pivotal phase II trial of atezolizumab for patients with alveolar soft part sarcoma (ASPS; ClinicalTrials.gov identifier: NCT03141684). Here, we report on...

The American Society of Clinical Oncology (ASCO) has expanded its Targeted Agent and Profiling Utilization Registry (TAPUR™) Study with two new developments: The study added its first antibody-drug co...

An anticancer drug secretion system based on engineered mammary organoids inhibits tumour recurrence in a mouse post-surgical breast cancer model and promotes mammary gland reconstruction.

Can we make radiotherapy faster and more accurate to keep ahead of the predicted rise in cancer cases?

Learn how rectal cancer patients with HER2 driven tumors benefited from an early stage clinical trial at MSK.

Scientists caution that more research is needed, but nearly all of the patients who responded to the personalized vaccine are still alive six years later.

Blocking a specific enzyme may unlock the immune system’s potential to attack tumors

Signal Transduction and Targeted Therapy - The cost of cure: cancer therapies sculpt somatic evolution and signaling landscapes in normal tissues

Researchers have found a way to make cancer-killing immune cells more powerful and precise. By adding specific signaling components, they boosted the cells’ readiness to attack tumors. Surprisingly, b...

The experimental therapy is designed to activate the immune system's ability to not only recognize and destroy cancer cells, but to remember them, so the body continues to attack tumors between treatm...